Living With Long COVID: LONGCOVID-EXPERIENCE

Long COVID Clinical Trial

Official title:

Living With Long COVID: LONGCOVID-EXPERIENCE Qualitative Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06118112
• Other study ID #: LONGCOVID EXPERIENCE
• Status: Recruiting
• Start date: September 18, 2023
• Est. completion date: December 30, 2024

Study information

• Verified date: November 2023
• Source: Corporacion Parc Tauli
• Contact: Pilar Peña, MD
• Phone: +34937231010
• Email: ppena[@]tauli.cat
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Background: One in ten people infected with COVID-19 presents persistent COVID, which consists of the presence of symptoms three months after the acute manifestations of COVID-19 and their persistence for at least two months, without being explained by an alternative diagnosis. The characteristics and clinical approach to persistent COVID syndrome are fairly well known, but not what the experience of people with persistent COVID is in relation to their daily life, their work life, and their experience with the healthcare received. Objective: to understand the experience of patients with persistent COVID in relation to the disease, the health care received and re-entry into the world of work Methods: Qualitative, descriptive, phenomenological study, based on individual interviews. The study protocol will be registered in Clinicaltrials.gov. People with persistent COVID treated at the Parc Taulí Hospital will be included. Sampling will be by convenience, purposive and snowball and the sample size will be determined by data saturation. Semi-structured individual or group interviews will be conducted and the data will be analyzed following a reflective thematic analysis (Brawn and Clarke). The preliminary report will be triangulated with some participants and with the results obtained from a scoping review carried out by the research team.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: December 30, 2024
• Est. primary completion date: September 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• women and men diagnosed with persistent COVID between March '20 to the present according to WHO criteria (persistent symptoms three months after the acute manifestations of COVID-19 and lasting at least two months and cannot be explained by an alternative diagnosis).
• treated at the Parc Taulí Hospital
• from 18 to 65 years Exclusion Criteria: -people who do not understand or can communicate in Catalan or Spanish.

Related Conditions & MeSH terms

• Experience, Life
• Long COVID

Locations

Country	Name	City	State
Spain	Corporació Sanitària Parc Taulí	Sabadell	Barcelona

Sponsors (2)

Lead Sponsor	Collaborator
Corporacion Parc Tauli	Universitat Autonoma de Barcelona

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Experience of the disease	How is living with LongCOVID. Assessed through semi-structured interviews.	Up to three years
Primary	Experience with healthcare received	How is the experience of patients with the healthcare received for their condition. Assessed through semi-structured interviews.	Up to three years
Primary	Experience with return to work	What were the barriers and facilitators for returning to work after the disease. Assessed through semi-structures interviews.	Up to three years